Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Gains from Investment Securities (2017 - 2025)

Historic Gains from Investment Securities for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q2 2025 value amounting to $15.0 million.

  • Crinetics Pharmaceuticals' Gains from Investment Securities rose 603.93% to $15.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $75.5 million, marking a year-over-year increase of 44398.5%. This contributed to the annual value of $13.7 million for FY2024, which is 822.55% up from last year.
  • According to the latest figures from Q2 2025, Crinetics Pharmaceuticals' Gains from Investment Securities is $15.0 million, which was up 603.93% from $4.1 million recorded in Q1 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Gains from Investment Securities peaked at $72.2 million during Q4 2024, and registered a low of -$708000.0 during Q4 2023.
  • In the last 5 years, Crinetics Pharmaceuticals' Gains from Investment Securities had a median value of $8.2 million in 2022 and averaged $10.5 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' Gains from Investment Securities soared by 13852909.68% in 2022, and later tumbled by 33600.0% in 2023.
  • Over the past 5 years, Crinetics Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $5.1 million in 2021, then tumbled by 94.13% to $300000.0 in 2022, then tumbled by 336.0% to -$708000.0 in 2023, then soared by 10290.82% to $72.2 million in 2024, then tumbled by 79.22% to $15.0 million in 2025.
  • Its Gains from Investment Securities was $15.0 million in Q2 2025, compared to $4.1 million in Q1 2025 and $72.2 million in Q4 2024.